Healthcare Professionals

Resolute Onyx™

Drug-Eluting Stent

  • Resolute Onyx DES

DELIVERING ADVANCED DES TECHNOLOGY TO YOUR PATIENTS

The Resolute Onyx™ drug-eluting stent is an advanced workhorse DES ready for your challenging coronary cases.

Exceptional Deliverability | Broadest DES Size Matrix | Enhanced Visibility
 

See how Resolute Onyx DES is different

See how Resolute Onyx DES is different.
More information (see more)Less information (see less)

Product Details

Two stent technologies join forces:
The only DES with Core Wire Technology and Continuous Sinusoid Technology

Continuous Sinusoid Technology
Flexible stent platform for outstanding flexibility and conformability

Continuous Sinusoid Technology

A single strand of cobalt alloy is formed into a sinusoid, wrapped in a helical pattern, and laser fused.

 

Core Wire Technology
Thinner struts with enhanced stent visibility for accurate stent placement

Core Wire Technology
 

Explore Continuous Sinusoid Technology


More information (see more)Less information (see less)

Engineered for exceptional deliverability1

Thinner struts, a low crossing profile, and an enhanced delivery system enable exceptional deliverability — without compromising structural strength.

20% More Deliverable | 36% More Pushable | 11% Thinner Struts
 

Enhanced delivery system advances acute performance1

  • Greater flexibility
  • Lower crossing profile
  • Exceptional deliverability with PowerTrac Technology
A well balanced delivery system

BROADEST DES SIZE MATRIX

A generous 2.0–5.0-mm size range means you can deliver advanced workhorse performance to more patients — and all sizes are 5 F compatible.

Broadest DES Size Matrix

4.50- and 5.00-mm sizes are not available in OTW.

The first DES with 2.0-mm sizes

The first DES with 2.0-mm sizes

The first DES with 4.5- and 5.0-mm sizes

Expanding options for patients with extra-large vessels

Predictable performance in XLV sizes—even at maximum overexpansion6

Resolute Onyx DES has minimal foreshortening compared with Synergy™* DES — for precise placement while maintaining coating integrity.7

Resolute Onyx™ DES

5.0 mm x 18 mm
Deployed to 5.75 per IFU maximum overexpansion

Resolute Onyx vs. Synergy

Synergy™* DES

4.0 mm x 20 mm
Deployed to 5.75 per IFU maximum overexpansion

Synergy vs. Resolute Onyx

Ready to learn more? Download the brochure.

pdf Resolute Onyx DES Brochure (.pdf)

1.3MB

Enhanced visibility for accurate stent placement

A platinum iridium core within the cobalt alloy shell enhances radiopacity in thinner struts—without compromising structural strength.

Cobalt alloy shell | Platinum iridium core material
 

Meaningful clinical evidence-generation and extensive real-world use

Meaningful clinical evidence-generation and extensive real-world use

Stent performance that endures

RESOLUTE POOLED9 ANALYSIS OF STENT THROMBOSIS (ARC DEF/PROB) THROUGH FIVE YEARS

RESOLUTE POOLED Analysis of Stent Thrombosis (ARC DEF/PROB) Through Five Years

RESOLUTE POOLED9 ANALYSIS OUTCOMES THROUGH FIVE YEARS

RESOLUTE POOLED Analysis Outcomes Through Five Years

Resolute™ ZES (N = 7618)

Resolute Onyx DES — excellent safety in real-world study

Resolute Onyx DES — excellent safety in real-world study

One-Year Clinical Outcomes of Patients Treated with Resolute Onyx DES vs. Resolute Integrity™ DES : an Interim Study of HOST-ONYX and HOST-RESOLINTE Registries11

One-Year Clinical Outcomes of Patients Treated with Resolute Onyx DES vs. Resolute Integrity™ DES : an Interim Study of HOST-ONYX and HOST-RESOLINTE Registries

Product Specifications

pdf Resolute Onyx DES — RX Coronary Stent System  (.pdf)

635KB

pdf Resolute Onyx DES — OTW Coronary Stent System (.pdf)

461KB

1

Based on bench test data. May not be indicative of clinical performance.

2

Compared with Resolute Integrity DES in benchtop testing. Data on file at Medtronic. May not be indicative of clinical performance.

3

Bench test data on file at Medtronic. May not be indicative of clinical performance. Testing performed on smallest diameters available for Abbott Xience Alpine™*, Biotronik Orsiro™*, Boston Scientific Promus Premier™*, Boston Scientific Synergy™*, Medtronic Resolute Integrity™, and Medtronic Resolute Onyx™ coronary stents. Biotronik Orsiro™* DES is not approved in the USA as of 21-FEB-2018. 

4

The Resolute Onyx stents should not be expanded to a diameter beyond the maximum labeled diameter listed on the label per the IFU. Do not dilate the 2.0-mm stents to greater than 3.25 mm. Postdilation required for overexpansion.

5

Price et al. JACC Cardiovascular Interventions. 2017;10(14):1381–1388.
Study only powered for TLF clinical endpoint. Rates are taken from KM estimates

6

The Resolute Onyx stents should not be expanded to a diameter beyond the maximum labeled diameter listed on the label per the IFU. Do not dilate the 4.5- and 5.0-mm stents to greater than 5.75 mm.

7

Based on bench test data. May not be indicative of clinical performance.

8

Based on net sales data of Resolute DES, Resolute Integrity DES, and Resolute Onyx DES through Q3FY2017.

9

Yeh et al. 5-year safety and efficacy of Resolute zotarolimus-eluting stent. JACC Cardiovascular Interventions. 2017;10:247–254.

10

Adapted from data published on http://www.ucr.uu.se/swedeheart/forskning-scaar/in-english/stent-reports as of March 28, 2017. ARC probable ST rates not reported in this analysis. Unadjusted, crude rates at different follow-up durations presented.

11

Kim et al. TCT 2017.

© 2018 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. ™* Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. For distribution in the USA only.